Attovia Q2 FY26 net loss widens to $20.7 million; revenue rises to $0.5 million
ATTO•Pipeline update
- ATTO-1310 showed preliminary proof of concept in chronic pruritus and high-itch atopic dermatitis; full Phase 1b data are due in Q4 2026.
Q2 results and expenses
- Attovia reported Q2 net loss widened 43.75% to $20.7 million, as R&D spending climbed 38.97% to $18.9 million.
- G&A expenses increased 10% to $3.3 million, while revenue was $0.5 million from R&D services under the EndPath license.
Cash position and IPO proceeds
- Cash, cash equivalents and marketable securities fell to $115.1 million at June 30 from $152.3 million at Dec. 31.
- An upsized IPO raised $332.4 million in gross proceeds; net proceeds of about $305.4 million extend the cash runway into 2030.
